{"schema_version":"secwatch.filing_event.v1","accession":"0001816590-24-000083","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.310910+00:00","generated_at":"2026-06-02T12:28:43.446449+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Compass Pathways reports positive Ph2 data for COMP360 psilocybin in PTSD; meets safety endpoint","bullets":["Phase 2 open-label study of 22 PTSD patients; single 25mg dose plus psychological support met primary safety endpoint.","No serious adverse events; common AEs mild: headache (50%), nausea (36.4%), crying (27.3%), fatigue (27.3%).","Mean CAPS-5 total score reduced 29.9 points at week 4 and 29.5 points at week 12 from baseline of 47.5.","Response rate (≥15-point CAPS-5 improvement) 81.8% at week 4 and 77.3% at week 12; remission rate 63.6% at week 4.","No patient withdrawals and no return to antidepressant medication during the 12-week study."],"urls":{"canonical":"https://secwatch.observer/filing/0001816590-24-000083","json":"https://secwatch.observer/filing/0001816590-24-000083.json","markdown":"https://secwatch.observer/filing/0001816590-24-000083.md","text":"https://secwatch.observer/filing/0001816590-24-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000181659024000083/0001816590-24-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000181659024000083/cmps-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:28:43.446449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}